Fixed and flexible doses of tavapadon significantly improved motor function compared with placebo in patients with Parkinson’s disease, according to a pair of phase 3 trials presented at the American ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist ...